Travere Therapeutics Inc at Bank of America Global Healthcare Conference Transcript
Welcome to the afternoon session of the Bank of America Healthcare Conference. I'm Greg Harrison, one of the biotech analysts here at BofA. And this afternoon, we have Travere Therapeutics with us. Representing Travere is Eric Dube, President and CEO; and Peter Heerma, Chief Commercial Officer. Eric is going to start off with a few preparing remarks and then we'll jump into Q&A.
Great. Well, thank you, Greg, and Bank of America for hosting us. This is an incredibly exciting year for Travere. We have been working on both continuing our commercial presence as well as preparing for what has been early signs of success with approval of FILSPARI in IgA nephropathy as well as completion of several Phase III programs within our pipeline, two of which are with sparsentan, both in FSGS and IgA nephropathy as well as the potential initiation of a Phase III with our pegtibatinase asset later this year in classical homocystinuria
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |